Diagnosis: Idiopathic Parkinsonism. Special instructions:
PRECAUTIONS:
When prescribing Zandopa, all known precautions and contraindications applicable to synthetic L-dopa formulation should be followed. Patients taking monoamine oxidase inhibitors should discontinue their use at least 2 weeks before starting Zandopa therapy. As with levodopa, it is recommended to periodically evaluate hepatic, hematopoietic, cardiovascular, and renal functions during extended therapy with Zandopa. Caution should be exercised when administering Zandopa to patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic, or endocrine disease, as well as in the presence of peptic ulcer or chronic narrow-angle glaucoma.
SIDE EFFECTS:
Possible side effects of Zandopa include nausea, anorexia, cardiac irregularities, orthostatic hypotension, weight gain, hot flushes, numerous dyskinesias, and psychiatric symptoms such as agitations, hallucinations, delusions, and nightmares. However, these side effects have not been observed to the same severity as with synthetic L-dopa formulations.
Dosage:
Zandopa should not be taken with milk. The prescribed dose of powder should be suspended in approximately half a glass of water (100ml), stirred, and then consumed immediately. A measure of 7.5gm (approximately) is provided in the container. The L-dopa content of Zandopa powder is readily soluble in water. Patients who have difficulty swallowing the bulk of the powder may be advised to stir the powder in water for nearly one minute and then strain it. The clear solution obtained may be consumed by the patient.
Zandopa is an Ayurvedic formulation derived from the seeds of Mucuna pruriens. It has a long history of use in Ayurvedic practice for CNS disorders and as a geriatric tonic. It is a natural and the richest known source of L-dopa, which is more readily bioavailable than synthetic L-dopa.
Reviews
There are no reviews yet.